Danaher Co. (NYSE:DHR) Shares Sold by Slow Capital Inc.

Slow Capital Inc. lessened its stake in shares of Danaher Co. (NYSE:DHR) by 3.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,027 shares of the conglomerate’s stock after selling 524 shares during the quarter. Slow Capital Inc.’s holdings in Danaher were worth $3,223,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Coronation Fund Managers Ltd. raised its position in Danaher by 29.9% in the second quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock worth $1,596,000 after acquiring an additional 1,470 shares in the last quarter. Ascent Group LLC lifted its stake in Danaher by 30.2% during the second quarter. Ascent Group LLC now owns 2,205 shares of the conglomerate’s stock valued at $551,000 after purchasing an additional 512 shares during the last quarter. Creative Planning boosted its holdings in Danaher by 6.0% during the second quarter. Creative Planning now owns 122,591 shares of the conglomerate’s stock worth $30,629,000 after buying an additional 6,969 shares in the last quarter. NewEdge Advisors LLC boosted its holdings in Danaher by 36.9% during the second quarter. NewEdge Advisors LLC now owns 49,460 shares of the conglomerate’s stock worth $12,357,000 after buying an additional 13,338 shares in the last quarter. Finally, Quarry LP grew its position in Danaher by 250.6% in the second quarter. Quarry LP now owns 298 shares of the conglomerate’s stock worth $74,000 after buying an additional 213 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 1.9 %

Danaher stock opened at $250.51 on Tuesday. The company’s fifty day moving average price is $235.33 and its two-hundred day moving average price is $253.62. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a one year low of $225.42 and a one year high of $281.70. The company has a market capitalization of $180.94 billion, a price-to-earnings ratio of 47.81, a PEG ratio of 4.43 and a beta of 0.83.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent analyst reports. Robert W. Baird cut their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. UBS Group reduced their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Guggenheim initiated coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price on the stock. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Finally, Barclays reduced their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $285.55.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.